Table of Content

1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS COVERED
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    FIGURE 2 KEY SECONDARY SOURCES
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primary interviews
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.2 MARKET ESTIMATION 
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
                    FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    FIGURE 7 MARKET SIZE ESTIMATION: MARKET
           2.2.2 GROWTH FORECAST
                    FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
                    FIGURE 9 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS 
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.8 IMPACT OF ECONOMIC RECESSION ON MARKET 
3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 11 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 CARRIER SCREENING INDUSTRY, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY MEDICAL CONDITION,  2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY TECHNOLOGY,  2023 VS. 2028 (USD MILLION)
    FIGURE 15 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 55)
    4.1 CARRIER SCREENING MARKET OVERVIEW 
          FIGURE 17 GROWING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET
    4.2 CARRIER SCREENING INDUSTRY FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023–2028 
          FIGURE 18 PREDESIGNED PANEL TESTING SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.3 NORTH AMERICA: MARKET,  BY PRODUCT & SERVICE AND COUNTRY, 2023 
          FIGURE 19 US AND PRODUCTS TO DOMINATE NORTH AMERICAN MARKET IN 2023
    4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: MARKET 
          FIGURE 20 US TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES:  CARRIER SCREENING MARKET
           5.2.1 DRIVERS
                    5.2.1.1 Increasing emphasis on early disease detection and prevention
                    5.2.1.2 Growing prevalence of genetic disorders
                    5.2.1.3 High risk of chromosomal abnormalities with advancing  maternal age
                                TABLE 2 GLOBAL INCIDENCE RATE OF TRISOMY
                    5.2.1.4 Increased focus on preconception and prenatal testing
                    5.2.1.5 Rising number of fertility clinics and IVF centers
                    5.2.1.6 Declining rate of fertility
                                TABLE 3 FERTILITY RATE (BIRTHS PER WOMAN), BY COUNTRY
           5.2.2 RESTRAINTS
                    5.2.2.1 Ethical concerns in preconception genetic carrier screening
                    5.2.2.2 High cost of carrier screening
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased awareness about reproductive health in emerging economies
                                FIGURE 22 HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012–2020
                    5.2.3.2 Integration with telehealth and digital health platforms
                    5.2.3.3 Increased number of collaborations and partnerships among healthcare organizations
                    5.2.3.4 Increasing number of government initiatives and policies toward genetic health improvement
                    5.2.3.5 Growing focus on health screening for rare diseases
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
                    5.2.4.2 Lack of standard guidelines for carrier screening
    5.3 TRENDS 
           5.3.1 LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING
    5.4 PRICING ANALYSIS 
          TABLE 4 INDICATIVE PRICING OF CARRIER SCREENING PRODUCTS/SERVICES
          TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 PORTER’S FIVE FORCES: CARRIER SCREENING INDUSTRY
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF SUPPLIERS
           5.7.4 BARGAINING POWER OF BUYERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 ECOSYSTEM/MARKET MAP 
          FIGURE 25 ECOSYSTEM/MARKET MAP: MARKET
          TABLE 7 ROLE IN ECOSYSTEM: CARRIER SCREENING INDUSTRY
          FIGURE 26 KEY PLAYERS IN MARKET
    5.9 TARIFF & REGULATORY LANDSCAPE 
          TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING MARKET
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
                    5.9.2.1 UK
                    5.9.2.2 France
           5.9.3 ASIA PACIFIC
                    5.9.3.1 Japan
                    5.9.3.2 India
    5.10 PATENT ANALYSIS 
           5.10.1 PATENT TRENDS FOR CARRIER SCREENING
                     FIGURE 27 PATENT TRENDS FOR CARRIER SCREENING, JANUARY 2013–DECEMBER 2023
           5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 28 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CARRIER SCREENING PATENTS, JANUARY 2013– DECEMBER 2023
    5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.11.1 REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS
                     FIGURE 29 REVENUE SHIFT FOR CARRIER SCREENING PRODUCTS/SERVICES
    5.12 KEY CONFERENCES & EVENTS 
           TABLE 9 DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
    5.13 TECHNOLOGY ANALYSIS 
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS
                     FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS
                     TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 31 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
                     TABLE 11 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
    5.15 TRADE ANALYSIS 
           TABLE 12 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION)
           TABLE 13 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION)
6 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE (Page No. - 80)
    6.1 INTRODUCTION 
          TABLE 14 CARRIER SCREENING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 SERVICES 
           6.2.1 RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET
                    TABLE 15 MARKET FOR SERVICES, BY REGION, 2021–2028 (USD MILLION)
    6.3 PRODUCTS 
           6.3.1 GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET
                    TABLE 16 KEY PLAYERS PROVIDING CARRIER SCREENING PRODUCTS
                    TABLE 17 MARKET FOR PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
7 CARRIER SCREENING MARKET, BY TYPE (Page No. - 84)
    7.1 INTRODUCTION 
          TABLE 18 CARRIER SCREENING INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    7.2 EXPANDED CARRIER SCREENING 
          TABLE 19 MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 20 MARKET FOR EXPANDED CARRIER SCREENING, BY REGION,  2021–2028 (USD MILLION)
           7.2.1 PREDESIGNED PANEL TESTING
                    7.2.1.1 Predesigned panel testing segment to command larger market share during forecast period
                                TABLE 21 PREDESIGNED PANEL TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.2.2 CUSTOMIZED PANEL TESTING
                    7.2.2.1 Better customization options for meeting specific customer requirements to drive segment
                                TABLE 22 CUSTOMIZED PANEL TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.3 TARGETED DISEASE CARRIER SCREENING 
           7.3.1 INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET
                    TABLE 23 MARKET FOR TARGETED DISEASE CARRIER SCREENING,  BY REGION, 2021–2028 (USD MILLION)
8 CARRIER SCREENING MARKET, BY MEDICAL CONDITION (Page No. - 90)
    8.1 INTRODUCTION 
          TABLE 24 CARRIER SCREENING INDUSTRY, BY MEDICAL CONDITION, 2021–2028 (USD MILLION)
    8.2 PULMONARY CONDITIONS 
           8.2.1 INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET
                    TABLE 25 LIVE BIRTH INCIDENCE OF CYSTIC FIBROSIS
                    TABLE 26 CARRIER SCREENING PRODUCTS/SERVICES FOR CYSTIC FIBROSIS
                    TABLE 27 MARKET FOR PULMONARY CONDITIONS, BY REGION,  2021–2028 (USD MILLION)
    8.3 HEMATOLOGICAL CONDITIONS 
           8.3.1 RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET
                    TABLE 28 MARKET FOR HEMATOLOGICAL CONDITIONS, BY REGION,  2021–2028 (USD MILLION)
    8.4 NEUROLOGICAL CONDITIONS 
           8.4.1 INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET
                    TABLE 29 GLOBAL PREVALENCE OF NEUROLOGICAL CONDITIONS
                    TABLE 30 CARRIER SCREENING PRODUCTS/SERVICES FOR NEUROLOGICAL CONDITIONS
                    TABLE 31 MARKET FOR NEUROLOGICAL CONDITIONS, BY REGION,  2021–2028 (USD MILLION)
    8.5 OTHER MEDICAL CONDITIONS 
          TABLE 32 MARKET FOR OTHER MEDICAL CONDITIONS, BY REGION,  2021–2028 (USD MILLION)
9 CARRIER SCREENING MARKET, BY TECHNOLOGY (Page No. - 98)
    9.1 INTRODUCTION 
          TABLE 33 CARRIER SCREENING INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    9.2 DNA SEQUENCING 
           9.2.1 DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
                    TABLE 34 DNA SEQUENCING USED BY MARKET PLAYERS
                    TABLE 35 MARKET FOR DNA SEQUENCING, BY REGION,  2021–2028 (USD MILLION)
    9.3 PCR 
           9.3.1 HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET
                    TABLE 36 PCR USED BY MARKET PLAYERS
                    TABLE 37 MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION)
    9.4 DNA MICROARRAYS 
           9.4.1 ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET
                    TABLE 38 DNA MICROARRAYS USED BY MARKET PLAYERS
                    TABLE 39 MARKET FOR DNA MICROARRAYS, BY REGION,  2021–2028 (USD MILLION)
    9.5 OTHER TECHNOLOGIES 
          TABLE 40 ADVANTAGES OF OTHER TECHNOLOGIES FOR CARRIER SCREENING
          TABLE 41 MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2021–2028 (USD MILLION)
10 CARRIER SCREENING MARKET, BY END USER (Page No. - 104)
     10.1 INTRODUCTION 
             TABLE 42 CARRIER SCREENING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS AND MEDICAL CENTERS 
             10.2.1 RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT
                        TABLE 43 MARKET FOR HOSPITALS AND MEDICAL CENTERS, BY REGION, 2021–2028 (USD MILLION)
     10.3 CLINICAL LABORATORIES 
             10.3.1 LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET
                        TABLE 44 MARKET FOR CLINICAL LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
     10.4 FERTILITY CLINICS 
             10.4.1 INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET
                        TABLE 45 MARKET FOR FERTILITY CLINICS, BY REGION,  2021–2028 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 46 MARKET FOR OTHER END USERS, BY REGION,  2021–2028 (USD MILLION)
11 CARRIER SCREENING MARKET, BY REGION (Page No. - 110)
     11.1 INTRODUCTION 
             TABLE 47 CARRIER SCREENING INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 32 NORTH AMERICA: CARRIER SCREENING MARKET SNAPSHOT
             TABLE 48 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 49 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 50 NORTH AMERICA: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 51 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 52 NORTH AMERICA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
             TABLE 53 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             TABLE 54 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             11.2.1 NORTH AMERICA: RECESSION IMPACT
             11.2.2 US
                        11.2.2.1 Increasing number of genetic diseases and rising healthcare expenditure to drive market
                                      TABLE 55 US: KEY MACROINDICATORS
                                      TABLE 56 US: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 57 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 58 US: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 59 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 60 US: MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION)
                                      TABLE 61 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increasing government and non-government funding to drive market
                                      TABLE 62 CANADA: KEY MACROINDICATORS
                                      TABLE 63 CANADA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 64 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 65 CANADA: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 66 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 67 CANADA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 68 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.3 EUROPE 
             TABLE 69 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
             11.3.1 EUROPE: RECESSION IMPACT
                        TABLE 70 EUROPE: CARRIER SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 71 EUROPE: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 72 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 73 EUROPE: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 74 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 75 EUROPE: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 76 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Increasing number of government initiatives and healthcare expenditures to drive market
                                      TABLE 77 GERMANY: KEY MACROINDICATORS
                                      TABLE 78 GERMANY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 79 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 80 GERMANY: MARKET FOR EXPANDED CARRIER SCREENING,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 81 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 82 GERMANY: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 83 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market
                                      TABLE 84 UK: KEY MACROINDICATORS
                                      TABLE 85 UK: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 86 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 87 UK: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 88 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 89 UK: MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION)
                                      TABLE 90 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Better healthcare infrastructure and higher expenditure for life science research to drive market
                                      TABLE 91 FRANCE: KEY MACROINDICATORS
                                      TABLE 92 FRANCE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 93 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 94 FRANCE: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 95 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 96 FRANCE: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 97 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Growing prevalence of chronic diseases and rising number of hospitals to drive market
                                      TABLE 98 ITALY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 99 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 100 ITALY: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 102 ITALY: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 103 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market
                                      TABLE 104 SPAIN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 105 SPAIN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 SPAIN: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 107 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 108 SPAIN: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 109 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 110 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
                        TABLE 111 REST OF EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 112 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 113 REST OF EUROPE: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 114 REST OF EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 115 REST OF EUROPE: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 116 REST OF EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 33 ASIA PACIFIC: CARRIER SCREENING MARKET SNAPSHOT
                        TABLE 117 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 118 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 119 ASIA PACIFIC: MARKET FOR EXPANDED CARRIER SCREENING,  BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 120 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 121 ASIA PACIFIC: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 122 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 INDIA
                        11.4.2.1 Growing incidence of rare diseases and declining fertility rates to drive market
                                      TABLE 123 INDIA: KEY MACROINDICATORS
                                      TABLE 124 INDIA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 125 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 126 INDIA: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 127 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 128 INDIA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 129 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 Rising focus on vaccine development and cancer research to drive market
                                      TABLE 130 CHINA: KEY MACROINDICATORS
                                      TABLE 131 CHINA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 132 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 133 CHINA: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 134 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 135 CHINA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 136 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 JAPAN
                        11.4.4.1 Rising geriatric population and growing government healthcare expenditure to drive market
                                      TABLE 137 JAPAN: KEY MACROINDICATORS
                                      TABLE 138 JAPAN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 139 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 140 JAPAN: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 141 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 142 JAPAN: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 143 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 144 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 145 REST OF ASIA PACIFIC: MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 146 REST OF ASIA PACIFIC: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 147 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 148 REST OF ASIA PACIFIC: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 149 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.5 REST OF THE WORLD 
             11.5.1 REST OF THE WORLD: RECESSION IMPACT
                        TABLE 150 REST OF THE WORLD: CARRIER SCREENING MARKET, BY PRODUCT &  2021–2028 (USD MILLION)
                        TABLE 151 REST OF THE WORLD: MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 152 REST OF THE WORLD: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 153 REST OF THE WORLD: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 154 REST OF THE WORLD: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 155 REST OF THE WORLD: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.5.2 LATIN AMERICA
                        11.5.2.1 Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market
                                      TABLE 156 DEFINITION OF RARE DISEASES IN VARIOUS COUNTRIES
                                      TABLE 157 LATIN AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 158 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 159 LATIN AMERICA: MARKET FOR EXPANDED CARRIER SCREENING,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 160 LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 161 LATIN AMERICA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                      TABLE 162 LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.5.3 MIDDLE EAST & AFRICA
                        TABLE 163 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 164 MIDDLE EAST & AFRICA: MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 165 MIDDLE EAST & AFRICA: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 166 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 167 MIDDLE EAST & AFRICA: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                        TABLE 168 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
                        11.5.3.1 GCC Countries
                                     11.5.3.1.1 Improved healthcare infrastructure and launch of genome projects to drive market
                                                     TABLE 169 GCC COUNTRIES: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                                     TABLE 170 GCC COUNTRIES: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                                     TABLE 171 GCC COUNTRIES: MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION)
                                                     TABLE 172 GCC COUNTRIES: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                                     TABLE 173 GCC COUNTRIES: MARKET, BY MEDICAL CONDITION,  2021–2028 (USD MILLION)
                                                     TABLE 174 GCC COUNTRIES: MARKET, BY END USER,  2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 174)
     12.1 OVERVIEW 
     12.2 KEY STRATEGIES/RIGHT TO WIN 
             12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
                        TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET
     12.3 MARKET SHARE ANALYSIS 
             TABLE 176 DEGREE OF COMPETITION: CARRIER SCREENING INDUSTRY
     12.4 REVENUE SHARE ANALYSIS 
             FIGURE 34 REVENUE SHARE ANALYSIS OF KEY PLAYERS
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 35 COMPANY EVALUATION MATRIX, 2022
             12.5.5 COMPANY FOOTPRINT
                        TABLE 177 OVERALL COMPANY FOOTPRINT
                        TABLE 178 PRODUCT FOOTPRINT
                        TABLE 179 REGIONAL FOOTPRINT
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 36 START-UP/SME EVALUATION MATRIX, 2022
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 180 DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING INDUSTRY
     12.7 COMPETITIVE SCENARIOS AND TRENDS 
             12.7.1 KEY DEALS
                        TABLE 181 KEY DEALS, JANUARY 2020–DECEMBER 2023
13 COMPANY PROFILES (Page No. - 184)
     13.1 KEY PLAYERS 
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)*
             13.1.1 NATERA, INC.
                        TABLE 182 NATERA, INC.: COMPANY OVERVIEW
                        FIGURE 37 NATERA, INC.: COMPANY SNAPSHOT (2022)
             13.1.2 QUEST DIAGNOSTICS INCORPORATED
                        TABLE 183 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
                        FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022)
             13.1.3 FULGENT GENETICS
                        TABLE 184 FULGENT GENETICS: COMPANY OVERVIEW
                        FIGURE 39 FULGENT GENETICS.: COMPANY SNAPSHOT (2022)
             13.1.4 INVITAE CORPORATION
                        TABLE 185 INVITAE CORPORATION: COMPANY OVERVIEW
                        FIGURE 40 INVITAE CORPORATION.: COMPANY SNAPSHOT (2022)
             13.1.5 EUROFINS SCIENTIFIC
                        TABLE 186 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             13.1.6 OPKO HEALTH, INC.
                        TABLE 187 OPKO HEALTH, INC.: COMPANY OVERVIEW
                        FIGURE 42 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022)
             13.1.7 THERMO FISHER SCIENTIFIC INC.
                        TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.8 MYRIAD GENETICS, INC.
                        TABLE 189 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
                        FIGURE 44 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
             13.1.9 ILLUMINA, INC.
                        TABLE 190 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 191 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
                        FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
             13.1.11 CENTOGENE N.V.
                        TABLE 192 CENTOGENE N.V.: COMPANY OVERVIEW
                        FIGURE 47 CENTOGENE N.V.: COMPANY SNAPSHOT (2022)
             13.1.12 DIASORIN S.P.A.
                        TABLE 193 DIASORIN S.P.A.: COMPANY OVERVIEW
                        FIGURE 48 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
             13.1.13 BGI
                        TABLE 194 BGI: COMPANY OVERVIEW
             13.1.14 OTOGENETICS
                        TABLE 195 OTOGENETICS: COMPANY OVERVIEW
             13.1.15 GENETECH
                        TABLE 196 GENETECH: COMPANY OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 OXY-GEN LABORATORY LLC
                        TABLE 197 OXY-GEN LABORATORY LLC: COMPANY OVERVIEW
             13.2.2 MEDGENOME
                        TABLE 198 MEDGENOME: COMPANY OVERVIEW
             13.2.3 AMBRY GENETICS.
                        TABLE 199 AMBRY GENETICS: COMPANY OVERVIEW
             13.2.4 ASPER BIOGENE
                        TABLE 200 ASPER BIOGENE: COMPANY OVERVIEW
             13.2.5 LIFELABS GENETICS
                        TABLE 201 LIFELABS GENETICS: COMPANY OVERVIEW
             13.2.6 EASYDNA
                        TABLE 202 EASYDNA: COMPANY OVERVIEW
             13.2.7 LIFECELL
                        TABLE 203 LIFECELL: COMPANY OVERVIEW
             13.2.8 CNC PATH LAB
                        TABLE 204 CNC PATH LAB: COMPANY OVERVIEW
             13.2.9 SIGNATURE DIAGNOSTICS INC.
                        TABLE 205 SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW
             13.2.10 MITERA
                        TABLE 206 MITERA: COMPANY OVERVIEW
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 226)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS